Clinical Laboratory News
-
Empowering Patient Care: Global Medical Kiosks Market Poised for Remarkable 14.8% CAGR, According to BCC Research
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
By BCC Research
-
Optimizing Monoclonal Antibody Production: Temperature And Osmolality’s Impact, Upcoming Webinar Hosted By Xtalks
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
-
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii. “At Castle, ...
-
Biomark provides business update and second quarter financial results
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
-
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh. This achievement follows a recent on-site inspection as part of the CAP’s Laboratory Accreditation Program. ...
-
Release of a new reference material for the detection of SARS-CoV-2 by RT-PCR.
The JRC released a new reference material for the detection of SARS-CoV-2 by real time RT-PCR. The material consists of a synthetic ssRNA (EURM-014) covering a fraction of the viral genome. It will be particularly useful for clinical or environmental diagnostic laboratories seeking quality and trust in their SARS-CoV-2 measurements. In 2020, the JRC issued a synthetic ssRNA molecule (EURM-019) ...
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
Kephera Diagnostics receives $417,074 grant award from the Massachusetts Life Sciences Center to accelerate development of its rapid COVID-19 Antigen Test
Today, the Baker-Polito Administration announced that more than $1.5 million has been awarded to four projects that seek to increase testing capacity and provide solutions for coronavirus testing. The funding is through the Accelerating Coronavirus Testing Solutions (A.C.T.S.) Program, designed and administered by the Massachusetts Life Sciences Center, which supports projects focused on two core ...
-
Why Innovation in Blood Testing Matters
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
-
CCRO Conducts First Clinical Trial with Head and Neck Surgery
Jeremy Richmon, MD is leading a new clinical trial sponsored by Alume, the Center for Clinical Research Operations' (CCRO) first clinical trial with Head and Neck Surgery. The trial involves using a tracer to help identify nerves intraoperatively. This type of cutting edge translational surgical innovation improves outcomes and ultimately the lives of our patients. The amount of coordination and ...
-
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
-
Join us at AACC 2022
As a leading company for AI-Driven IVD equipments, Reetoo will be attending AACC (American Association for Clinical Chemistry), which will take place at the McCormick Place Convention Center in Chicago from July 26 to 28. We will bring our latest products to the exhibition as below, and look forward to meeting you at our booth #4060. RT-F600: Automatic Vaginal Secretion Analyzer ...
-
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement, gene editing and allogeneic cell therapies, today announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A. Hemophilia A is caused by the lack of the blood ...
-
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and ...
By PAVmed Inc.
-
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the Company and presented preliminary financial results for the three months ended March 31, 2022. Conference Call ...
By PAVmed Inc.
-
Meet the Molds - Important aeroallergens in allergy testing
Despite being defined more than 100 years ago; atmospheric molds have remained undervalued as an important aeroallergen in allergy testing. Of the estimated number of more than 1 million different fungal species, approximately 80 species have been linked with respiratory allergy. However, epidemiologic studies have suggested that the prevalence of allergies to molds is less than 3% in an allergic ...
-
Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced real-world data on Endari®, the company’s prescription-grade L-glutamine oral powder, in preventing acute complications from sickle cell disease (SCD) and hemolysis in pediatric and adult patients in French Guiana and Qatar. The data ...
-
OncoDNA and Synlab Partner to Facilitate Access to Comprehensive Biomarker Testing for Cancer Therapy Selection in Germany
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, EUROPE’S LEADING CLINICAL LABORATORY AND MEDICAL DIAGNOSTIC SERVICES PROVIDER. ...
By OncoDNA S.A.
-
Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar ...
-
A Brand New Collaboration Between Emovi and The Geneva Foundation
In partnership with The Geneva Foundation and supporting grant from the Quebec Ministry of Economy and Innovation, Emovi will launch the 24-month clinical project within US Army clinics at Fort Bragg and High Point University, North Carolina, USA Emovi, Inc., a leading medical device developer and manufacturer for orthopaedics, announced today a clinical collaboration with the US Army in ...
By Emovi
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you